CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. [electronic resource]
Producer: 20201007Description: 1599-1612 p. digitalISSN:- 1476-5551
- Adenine -- analogs & derivatives
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Ataxia Telangiectasia Mutated Proteins -- genetics
- CRISPR-Cas Systems
- Cell Line, Tumor
- Chromosome Deletion
- Chromosomes, Human, Pair 11 -- genetics
- Drug Synergism
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell -- genetics
- Mice
- Mutagenesis, Site-Directed -- methods
- Mutation
- Phthalazines -- pharmacology
- Piperazines -- pharmacology
- Piperidines
- Poly (ADP-Ribose) Polymerase-1 -- antagonists & inhibitors
- Poly(ADP-ribose) Polymerase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-bcr -- antagonists & inhibitors
- Pyrazoles -- pharmacology
- Pyrimidines -- pharmacology
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.